Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 288, 84-95
Abstract
No abstract availableKeywords
Funding Information
- Swedish Cancer Society (14-0298, 14/474, 15/350, 15/746)
- Swedish Research Council (2015-02509, 2015-02353)
- Swedish Agency for Innovation VINNOVA (2016-04060)
This publication has 38 references indexed in Scilit:
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of actionBreast Cancer Research, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Structural basis for high-affinity HER2 receptor binding by an engineered proteinProceedings of the National Academy of Sciences of the United States of America, 2010
- Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applicationsFEBS Letters, 2010
- Design of an Optimized Scaffold for Affibody MoleculesJournal of Molecular Biology, 2010
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Effects of HER2-Binding Affibody Molecules on Intracellular Signaling PathwaysTumor Biology, 2006
- Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometryProtein Science, 2005